Adalimumab Increases Follicle Reserve and Follicle Development in Rat Ovary: The Effect of Adalimumab on Ovarian Reserve

Selçuk Kaplan 1, Ahmet Türk 2

1. Obstetrics and Gynaecology, Adıyaman University Faculty of Medicine, Adıyaman, TUR 2. Histology and Embryology, Adıyaman University Faculty of Medicine, Adıyaman, TUR

Corresponding author: Selçuk Kaplan, kaplan_2384@hotmail.com

Abstract

Introduction
Adalimumab is used in the treatment of many chronic inflammatory diseases, especially rheumatoid arthritis. The aim of this experimental study is to determine the histological and biochemical effects of adalimumab on rat ovary.

Methods
Wistar albino female rats were randomly divided into three groups prior to the experiment: a healthy control group, a 2 mg/kg adalimumab group, and a 5 mg/kg adalimumab group. Then, histopathological findings and biochemical examinations were made in the ovaries of the rats. Hematoxylin-eosin staining, morphometric examination, and Masson trichrome staining were performed. Antimullerian hormone (AMH) levels were measured in the biochemical examination.

Results
Ovarian follicle count and AMH level were significantly higher in the groups given low-dose adalimumab and high-dose adalimumab (p <0.001). In addition, fibrosis decreased in proportion to the dose of adalimumab (p <0.001).

Conclusion
Adalimumab is an important biological agent that contributes to the preservation of ovarian function by increasing ovarian follicle reserve and has shown that it can help preserve ovarian reserve in women of reproductive age suffering from chronic inflammatory diseases.

Categories: Obstetrics/Gynecology
Keywords: adalimumab, ovarian follicle reserve, ovarian toxicity, rat, rheumatoid arthritis

Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disease that is common in women of reproductive age. Subfertility (pregnancy duration longer than 12 months despite regular unprotected intercourse) is a common problem in women with RA; approximately 40% of women with RA suffer from subfertility [1-3]. Women with RA are more often nulliparous than healthy women [4]. Among patients with RA, subfertility has been associated with the use of non-steroid anti-inflammatory drugs (NSAIDs) and prednisone [2]. However, little is known about how biological agents, which have been frequently used in patients with RA in recent years, affect ovarian function and fertility. In addition, the low age of menopause in women with RA has been evaluated in relation to premature ovarian failure [5-6]. In a recent study, it was shown that ovarian reserve decreases in women with RA [7].

Many important markers, such as menstrual cycle pattern, primordial ovarian count, hormonal value (follicle-stimulating hormone (FSH), luteinizing hormone (LH), and estradiol), and anti-mullerian hormone (AMH) are used to determine ovarian reserve [8]. In histological examinations, the number of follicles with hematoxylin-eosin staining and the primordial follicle reserve are important parameters for determining ovarian reserve [9]. AMH is produced by the granulosa cells of preantral and antral follicles and is one of the best ovarian reserve markers independent of the menstrual cycle [10]. Moreover, AMH can be used to indicate ovarian reserve after gonadotoxic therapy such as chemotherapy, radiotherapy, or surgery.

Adalimumab, a fully human immunoglobulin (Ig) G1 neutralizing monoclonal antibody specific to tumor necrosis factor-α (TNF-α) is used in the treatment of many chronic inflammatory diseases, especially RA [11-12]. A recent study evaluating ovarian reserve in patients with juvenile RA using ultrasonographic
examination and AMH, LH, and FSH levels showed that ovarian functions were not affected in patients using biological agents such as adalimumab and etanercept [13]. However, there are very few studies on this subject. As such, the aim of this experimental study was to determine the histological and biochemical effects of adalimumab on rat ovaries.

Materials And Methods

The experiments in this study were approved by our local animal ethics committee and carried out in accordance with the National Institutes of Health animal research guidelines (Date: 04.06.2020, Ethics committee number: 2020/022).

Animals and experimental protocol

In the present study, 21 10- to 12-week-old Wistar albino female rats, weighing 250-280 g, were divided into three groups of seven animals each. To enable adaptation, the animals were placed in the cage for seven days without treatment at room temperature 22 ± 2°C, with 12 hours of dark and 12 hours of light, and water and feed. Similar conditions were maintained throughout the experiment.

Sixty mg/kg ketamine hydrochloric acid (Ketalar Eczacibasi Warner-Lambert Pharmaceutical, Istanbul, Turkey) and 7 mg/kg xylazine hydrochloric acid (Rompun, Bayer, Istanbul, Turkey) were administered intramuscularly to all rats as anesthetics. For Group 1 (control group) (n = 7), after the adnexa was localized with the right and left uterine horns, the abdominal wall was closed with 4-0 nylon sutures. No other actions were applied during the experiment. For Group 2 (low-dose adalimumab group) (n = 7), after the adnexa was localized with the right and left uterine horns, the abdominal wall was closed with 4-0 nylon sutures, and 2 mg/kg adalimumab intraperitoneal was given every day for four weeks. For Group 3 (high-dose adalimumab group) (n = 7), after the adnexa was localized with the right and left uterine horns, the abdominal wall was closed with 4-0 nylon sutures, and 5 mg/kg adalimumab intraperitoneal was given every day for four weeks.

Histopathological evaluation

Hematoxylin and Eosin Staining and Follicular Classification

Ovarian tissues were fixed with 10% formaldehyde and embedded in paraffin blocks after a routine tissue placement procedure. Then, 4-6 µm sections were obtained from the paraffin blocks and stained with hematoxylin and eosin (H&E), and the prepared samples were photographed by counting the follicles using a Leica DMS500 microscope (Leica Microsystems, Wetzlar, Germany) [14]. In accordance with a previous study [15], the follicles were classified as follows: primordial follicle (an oocyte surrounded by a flattened single layer of granulosa cell), a primary follicle (an oocyte surrounded by a cuboidal single layer of granulosa cell), a secondary follicle (multiple layers of cuboidal granulosa cells and an oocyte without antral space), and an antral follicle (oocyte with antral space or multiple (four) layers of granulosa cells). Oocytes with a fragmented nucleus, degenerated oocytes, or antral follicles with irregular granulosa cells were considered atretic [16]. Each follicle with the above-mentioned characteristics was counted once, and groups were formed according to the number of follicles.

Masson’s Trichrome Staining

Masson’s trichrome dye was used for fibrosis grading and evaluated semi-quantitatively. First, the 4 µm deparaffinized sections were stained with an acid dye (acid fuchsin). Then, they were treated with phosphomolybdic acid, and, finally, they were stained with methyl blue. Old collagen fibers were dyed red, and the newly formed collagen fibers were blue. Accordingly, the following scale was used: 0 = no fibrosis, +1 = low fibrosis, +2 = moderate fibrosis, and +3 = severe fibrosis [17].

Biochemical examination

Assay of Plasma AMH Concentrations

The AMH levels (ng/mL) of the serum samples were determined by the Enzyme-Linked ImmunoSorbent Assay (ELISA) method (Thermo Scientific Multiskan GO, Finland) using commercially available rat ELISA kits. All samples were tested using the same assay. The sensitivity of the assay was 0.10 ng/mL, and the assay ranges were 0.3-40 ng/mL.

Statistical analysis

Statistical analysis was performed using SPSS® Statistics 22 for Windows software (IBM Corp., Armonk, NY). The Shapiro-Wilk test was used as a normal distribution test. The one-way analysis of variance (ANOVA) test (the post-hoc test Bonferroni test) was used to analyze data that conformed to the normal distribution. The chi-square test was used to analyze the qualitative data, and p < 0.05 was considered significant.

Results
**Histopathological results**

*Hematoxylin-Eosin Staining and Morphometric Examination Results*

Based on an evaluation of the H&E staining, the total number of follicles was increased in the low- and high-dose adalimumab groups than in the control group. While there were statistically significant differences between the numbers of primordial, primary, secondary, and antral follicles in the groups, there were no significant differences between the corpus luteum numbers (Table 1, Figure 1).

| Group     | Primordial Follicle | Primary Follicle | Secondary Follicle | Antral Follicle | Corpus Luteum |
|-----------|---------------------|------------------|--------------------|----------------|---------------|
| **Control Group** | Mean±SD 5,96±0,23 | 3,12±0,13 | 6,99±0,66 | 1,20±0,037 | 19,88±0,43 |
|           | Median 6,01         | 3,14          | 7,03              | 1,20          | 20,02         |
| **LD ADA** | Mean±SD 6,90±0,41 | 4,05±0,14 | 8,88±0,23 | 1,28±0,042 | 15,69±0,96 |
|           | Median 7,09         | 4,10          | 9,02              | 1,28          | 18,01         |
| **HD ADA** | Mean±SD 10,91±1,06 | 4,92±0,20 | 14,28±1,32 | 2,10±0,30 | 13,56±0,89 |
|           | Median 11,10        | 4,90          | 14,90             | 2,21          | 15,60         |
| **p**     | <0.001              | <0.001        | <0.001            | <0.001        | 0.063         |

**TABLE 1: Number of follicles by groups**

SD: Standard deviation; LD ADA: Low-dose adalimumab group; HD ADA: High-dose adalimumab group

There was a significant difference in fibrosis severity between the groups (Table 2, Figure 2). While 14.3% of the high-dose adalimumab group had mild fibrosis, 28.6% of the control group had mild fibrosis, the low-dose adalimumab group 57.1% had moderate fibrosis, and 42.9% had severe fibrosis (Table 2). Fibrosis severity was lower in the low- and high-dose adalimumab groups than in the control group and lower in the high-dose adalimumab group than in the low-dose adalimumab group (p < 0.001).

**Masson Trichrome Staining Results**
| Group               | Control Group | Low-Dose ADA | High-Dose ADA |
|---------------------|---------------|--------------|---------------|
| n                   | 0             | 4            | 6             |
| %                   | 0.0           | 57.1         | 85.7          |
| Fibrosis            |               |              |               |
| None                | 0             | 0            | 6             |
| Low                 | 1             | 4            | 1             |
| Mild                | 3             | 3            | 0             |
| Severe              | 3             | 0            | 0             |
| p                   |               |              | <0.001        |

**TABLE 2: Comparison of fibrosis severity according to experimental groups**

ADA: Adalimumab

**FIGURE 2:** 2a: Control group; 2b: Low-dose adalimumab group; 2c: High-dose adalimumab group

CL: Corpus luteum, F: Follicle, CT: Connective tissue, A: Antrum, Black arrow: Connective tissue increase

The post-hoc analysis of the differences in follicle numbers between the groups is shown in Table 3. The number of primordial follicles was larger in the low- and high-dose adalimumab groups as compared to the control group (p < 0.001). In addition, the number of primordial follicles was larger in the high-dose adalimumab group than in the low-dose adalimumab group (p = 0.043). In addition, primary, secondary, and antral follicle numbers were higher in the low- and high-dose adalimumab groups than in the control group (p < 0.001). Moreover, the primary follicle number (p < 0.001) and the secondary follicle number (p = 0.002) were larger in the high-dose adalimumab group than those in the low-dose adalimumab group (Table 3, Figure 3).
| Dependent Variable | Group       | Mean Difference | p  |
|--------------------|-------------|-----------------|----|
| High-Dose ADA      | Control     | 1,79*           | <0,001 |
|                    | LD ADA      | 0,87*           | <0,001 |
|                    | HD ADA      | -1,79*          | <0,001 |
| Primary Follicle   | Control     | -0,92*          | <0,001 |
|                    | LD ADA      | -0,87*          | <0,001 |
|                    | HD ADA      | 0,92*           | <0,001 |
|                    | Control     | 7,29*           | <0,001 |
| LD ADA             | Control     | 5,39*           | <0,001 |
|                    | HD ADA      | -7,29*          | <0,001 |
| Low-Dose ADA       | Control     | -1,89*          | 0,002 |
|                    | LD ADA      | -5,39*          | <0,001 |
|                    | HD ADA      | 1,89*           | 0,002 |
| High-Dose ADA      | Control     | 4,95*           | <0,001 |
|                    | LD ADA      | 4,00*           | <0,001 |
|                    | HD ADA      | -4,95*          | <0,001 |
| Secondary Follicle | Control     | -0,40*          | <0,001 |
|                    | LD ADA      | -0,40*          | <0,001 |
|                    | HD ADA      | 0,94*           | 0,043 |
|                    | Control     | 0,94*           | 0,043 |
| Low-Dose ADA       | Control     | 0,08            | 1,000 |
|                    | LD ADA      | -0,08           | 1,000 |
|                    | HD ADA      | -0,81*          | <0,001 |
|                     | Control     | 0,08            | 1,000 |

* groups with differences

**TABLE 3: Post-hoc analysis of experimental groups**
ADA: Adalimumab, LD: Low dose, HD: High dose
Biochemical evaluation

AMH Level

After adalimumab administration, the mean AMH level increased in both groups as compared to the control group (Table 4). The AMH level increased in the high-dose adalimumab group as compared to the low-dose adalimumab group (p = 0.007). Total follicle number and AMH values were correlated in the high-dose adalimumab group (p = 0.041). However, there was no statistically significant difference in other groups (p > 0.05) (Figure 4).

|                | Control Group | Low-Dose ADA | High-Dose ADA |
|----------------|---------------|--------------|---------------|
| AMH (ng/mL)    | 6.14±0.39     | 9.83±0.51    | 13.71±0.62*   |
| Total Follicle | 17.27±0.74    | 21.11±1.13   | 32.21±2.72**  |

TABLE 4: Comparison of AMH values according to experimental groups

ADA: Adalimumab; AMH: Anti Mullerian hormone; * p=0.007, ** p=0.041
Discussion

The biochemical and histopathological findings in our study showed that adalimumab increased the number of follicles in the ovary and decreased fibrosis. Meanwhile, the AMH level, which is a valuable marker showing follicle reserve, increased in rats given a high dose of adalimumab.

The inflammation process is related to the production of cytokines and chemokines, and the associated damage caused by leukocytes. TNF-α is an important cytokine that plays a role in ovarian ischemia-reperfusion injury. An increase in TNF-α levels in the ovaries causes leukocyte infiltration and leads to ovarian tissue damage and a decrease in ovarian reserve [18]. Another study investigating the effects of the biological agent etanercept on an ovarian ischemia-reperfusion injury showed that etanercept reduced injury effect on ovarian damage [19]. Many studies have shown that TNF-α inhibitors improve infertility treatment outcomes [20-21]. In our study, the increase in ovarian reserve in rats given adalimumab can be explained in light of this information. AMH is a marker used for preantral follicle reserve in the ovarian pool [22] and is secreted from granulosa cells of antral follicles [10]. Therefore, it is not coincidental that the increase in AMH, another marker showing an increase in ovarian reserve, was higher in the high-dose adalimumab group. In women with recurrent pregnancy loss, an increase in the T helper type 1 (Th1) cell count in peripheral blood lymphocytes has been found [23]. Furthermore, an increase in the Th1/Th2 ratio may cause implantation failure and spontaneous abortion [24]. TNF-α inhibitors increase the success of in vitro fertilization by changing the Th1/Th2 balance [21]. In a study of 25 RA patients who received anti-TNF-α inhibitor therapy, the spontaneous pregnancy duration was shortened in women treated with biological agents [25]. The increase in ovarian follicle reserve in rats given adalimumab in our study supports these publications.

Ovarian fibrosis plays an important role in the physiological and pathological processes of the ovaries. A fibrotic focus in the ovary seriously affects reproductive health and quality of life in women. Ovarian fibrosis may cause premature ovarian failure by reducing ovarian functions [26]. It has been reported that follicular atresia, which causes ovarian dysfunction, may be associated with increased TNF-α and other proinflammatory cytokines in rats with experimentally developed polycystic ovary [27-29]. In this study, we performed laparotomy for ovarian fixation in all groups. While fibrosis developed secondary to this operation in the control group, fibrosis decreased in proportion to the dose of adalimumab. This effect of
Adalimumab may be related to the inhibition of TNF-α by adalimumab. This activity may suggest that it may be a treatment option for early recovery after pelvic surgeries and for women suffering from premature ovarian insufficiency.

Conclusions
Adalimumab is an important biological agent that contributes to the preservation of ovarian function by increasing ovarian follicle reserve. This study demonstrated that it may help preserve ovarian reserve in women of reproductive age suffering from chronic inflammatory diseases. As a result, the findings of our study should be supported by a larger sample of cases and human studies.

Additional Information
Disclosures
Human subjects: All authors have confirmed that this study did not involve human participants or tissue. Animal subjects: Adiyaman University Experimental Animal Center Issued protocol number Ethics committee no: 2020/022. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References
1. Clowse ME, Chakravarty E, Costenbader KH, Chambers C, Michaud K: Effects of infertility, pregnancy loss, and patient concerns on family size of women with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res. 2012, 64:668-674. 10.1002/acr.21595
2. Brouwer J, Hazes JM, Laven JS, Dolhain RJ: Fertility in women with rheumatoid arthritis: influence of disease activity and medication. Ann Rheum Dis. 2015, 74:1836-1841. 10.1136/annrheumdis-2014-205583
3. Brouwer J, Fleurbaij R, Hazes JM, Laven JS Dolhain RJ: OP0165 subfertility in female rheumatoid arthritis patients is often unexplained or caused by anovulation. Ann Rheum Dis. 2015, 74:151-152. 10.1136/annrheumdis-2015-eular.2052
4. Del Junco DJ, Annegers JF, Coulam CB, Luthra HS: The relationship between rheumatoid arthritis and reproductive function. Br J Rheumatol. 1989, 28:33-42. 10.1095/rheumatology.xxviii.suppl_1.33
5. Luisi S, Orlandini C, Regini C, Pizzo A, Vellucci F, Petraglia F: Premature ovarian insufficiency: from pathogenesis to clinical management. J Endocrinol Invest. 2015, 38:597-603. 10.1007/s40618-014-0231-1
6. Saglam F, Oral ED, Ersoy R, Koca C, Ergin M, Erel O, Cakir B: Anti-Müllerian hormone as a marker of premature ovarian aging in autoimmune thyroid disease. Gynecol Endocrinol. 2015, 31:165-168. 10.3109/09513590.2014.973391
7. Henes M, Froeschlin J, Taran FA, et al.: Ovarian reserve alterations in premenopausal women with chronic inflammatory rheumatic diseases: impact of rheumatoid arthritis, Behçet’s disease and spondyloarthritides on anti-Müllerian hormone levels. Rheumatology. 2015, 54:1709-1712. 10.1093/rheumatologykev124
8. Beniam A, Guralp O, Uzan DD, Okyar A, Sahmey S: The effect of repeated administration of methotrexate (MTX) on rat ovary: measurement of serum antimullerian hormone (AMH) levels. Gynecol Endocrinol. 2015, 29:226-229. 10.3109/09513590.2012.738725
9. Hu F, Schatt L, Kozlowski C, Regan K, Dybdal N, Schutter MM: Ovarian toxicity assessment in histopathological images using deep learning. Toxicol Pathol. 2020, 48:350-361. 10.1177/0192633319877871
10. Feyereisen E, Mendez Lozano DH, Taieb J, Hesters L, Frydman R, Fanchin R: Anti-Müllerian hormone clinical insights into a promising biomarker of ovarian follicular status. Reprod Biomed Online. 2006, 12:695-703. 10.1016/S1472-6483(10)61081-4
11. Burmester GR, Landewe R, Genovese MC, Friedman AW, Pfeifer ND, Variath NA, Laven JS, Dolhain RJ: Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis. Ann Rheum Dis. 2017, 76:414-417. 10.1136/annrheumdis-2016-209522
12. Ferreira GRV, Tomioka RB, Aikawa NE, et al.: Effects of spirulina on cyclophosphamide-induced ovarian toxicity in rats: biochemical and histomorphometric evaluation of the ovary. Biochem Res Int. 2013, 2013:764262.
13. Luo LL, Huang J, Fu YC, et al.: Effects of tea polyphenols on ovarian development in rats. Toxicol Pathol. 2020, 48:350-361. 10.1177/0192633319877871
14. Luong TA, Khoo BC, Loo L, et al.: Anti-Müllerian hormone as a marker of premature ovarian aging in autoimmune thyroid disease. Gynecol Endocrinol. 2015, 31:165-168. 10.3109/09513590.2014.973391
15. Clowse ME, Chakravarty E, Costenbader KH, Chambers C, Michaud K: Effects of infertility, pregnancy loss, and patient concerns on family size of women with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res. 2012, 64:668-674. 10.1002/acr.21595
improves live birth rates in women with recurrent spontaneous abortion. Am J Reprod Immunol. 2008, 60:8-16. 10.1111/j.1600-0897.2008.00585.x

19. Ramallo E, Marques T, Prats N, Jordi Beleta, Kunkel SL, Godessart N: Resident cell chemokine expression serves as the major mechanism for leukocyte recruitment during local inflammation. J Immunol. 2002, 169:6467-6473. 10.4049/jimmunol.169.11.6467

20. Winger EE, Reed JL, Ashouh S, Ahuja S, El-Toukhy T, Taranissi M: Treatment with adalimumab (Humira) and intravenous immunoglobulin improves pregnancy rates in women undergoing IVF. Am J Reprod Immunol. 2009, 61:113-120. 10.1111/j.1600-0897.2008.00669.x

21. Clark DA: Anti-TNFα therapy in immune-mediated subfertility: state of the art. J Reprod Immunol. 2010, 85:15-24. 10.1016/j.jri.2010.01.007

22. Freeman EW, Sammel MD, Lin H, Gracia CR: Anti-Mullerian hormone as a predictor of time to menopause in late reproductive age women. J Clin Endocrinol Metab. 2012, 97:1673-1680. 10.1210/jc.2011-3032

23. Hill JA, Polgar K, Anderson JD: T-helper 1-type immunity to trophoblast in women with recurrent spontaneous abortion. JAMA. 1995, 273:1933-1936. 10.1001/jama.1995.03520480053039

24. Krishnan L, Guilbert LJ, Wegmann TG, Belosevic M, Mosmann TR: T helper 1 response against Leishmania major in pregnant C57BL/6 mice increases implantation failure and fetal resorptions. Correlation with increased IFN-gamma and TNF and reduced IL-10 production by placental cells. J Immunol. 1996, 156:653-662.

25. Shimada H, Kameda T, Kanenishi K, et al.: Effect of biologic disease-modifying anti-rheumatic drugs for patients with rheumatoid arthritis who hope to become mothers. Clin Rheumatol. 2019, 58:1455-1458. 10.1007/s10067-019-04450-3

26. Miao ZL, Yong LG, Wang X, et al.: The intervention effect of rosiglitazone in ovarian fibrosis of PCOS rats. Biomed Environ Sci. 2012, 25:46-52. 10.3967/0895-3988.2012.01.007

27. Rezvanfar MA, Saadat S, Saadat HA, Baeei M, Abdollahi M: Mechanistic links between oxidative/nitrosative stress and tumor necrosis factor alpha in letrozole-induced murine polycystic ovary: biochemical and pathological evidences for beneficial effect of pioglitazone. Hum Exp Toxicol. 2012, 31:887-897.

28. Rezvanfar MA, Saadat S, Saadat HA, et al.: Cellular and molecular mechanisms of pentoxifylline’s beneficial effects in experimental polycystic ovary. Theriogenology. 2015, 83:968-977. 10.1016/j.theriogenology.2014.11.034

29. Rezvanfar MA, Saadat HA, Gooshe M, Abdolghaffari AH, Baeei M, Abdollahi M: Ovarian aging like phenotype in the hyperandrogenism-induced murine model of polycystic ovary. Oxid Med Cell Longev. 2014, 2014:948951. 10.1155/2014/948951